• 1. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

Introduction to 1-(cyclobutylcarbonyl)piperidine-3-carboxylic Acid (CAS No. 926214-73-5)

1-(cyclobutylcarbonyl)piperidine-3-carboxylic Acid, identified by the Chemical Abstracts Service Number (CAS No.) 926214-73-5, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical research and chemical synthesis. This compound belongs to the piperidine class of heterocyclic amines, characterized by a six-membered ring containing one nitrogen atom and five carbon atoms. The presence of a cyclobutylcarbonyl group at the 1-position and a carboxylic acid moiety at the 3-position imparts unique chemical properties that make it a valuable intermediate in the development of novel therapeutic agents.

The structural features of 1-(cyclobutylcarbonyl)piperidine-3-carboxylic Acid contribute to its versatility in synthetic chemistry. The cyclobutyl group, being a rigid cyclic structure, enhances the metabolic stability of derivatives, while the piperidine ring provides a suitable scaffold for further functionalization. These attributes have positioned this compound as a key building block in medicinal chemistry, particularly in the design of small-molecule drugs targeting neurological and inflammatory disorders.

Recent advancements in drug discovery have highlighted the importance of piperidine derivatives in addressing unmet medical needs. Researchers have leveraged the structural framework of 1-(cyclobutylcarbonyl)piperidine-3-carboxylic Acid to develop compounds with enhanced pharmacokinetic profiles and improved binding affinity to biological targets. For instance, studies have demonstrated its utility in synthesizing potent inhibitors of enzymes involved in pain signaling and neurodegenerative diseases. The compound’s ability to undergo further derivatization has enabled the creation of libraries of analogs with tailored biological activities.

The synthesis of 1-(cyclobutylcarbonyl)piperidine-3-carboxylic Acid involves multi-step organic reactions that require precise control over reaction conditions. Common synthetic routes include cyclization reactions followed by functional group transformations to introduce the cyclobutyl and carboxylic acid moieties. The use of advanced catalytic systems has improved the efficiency and scalability of these processes, making it feasible for industrial-scale production. Additionally, green chemistry principles have been integrated into synthetic methodologies to minimize waste and reduce environmental impact.

In vitro studies have revealed that derivatives of 1-(cyclobutylcarbonyl)piperidine-3-carboxylic Acid exhibit promising pharmacological effects. For example, modifications at the 3-position have been explored to enhance receptor binding interactions, leading to compounds with potential applications in treating autoimmune diseases and chronic pain conditions. Furthermore, computational modeling has been employed to predict the binding modes of these derivatives with target proteins, facilitating rational drug design.

The pharmaceutical industry has shown particular interest in 1-(cyclobutylcarbonyl)piperidine-3-carboxylic Acid due to its role as a precursor for biologically active molecules. Collaborative efforts between academic researchers and industrial chemists have accelerated the development pipeline for novel therapeutics derived from this compound. Preclinical trials are underway to evaluate the safety and efficacy of several candidate drugs based on its structural scaffold, with initial results indicating encouraging biological activity.

Looking ahead, the future prospects for 1-(cyclobutylcarbonyl)piperidine-3-carboxylic Acid are promising, driven by ongoing research into its applications in drug development. Innovations in synthetic methodologies and high-throughput screening techniques will continue to expand its utility across various therapeutic areas. As our understanding of disease mechanisms evolves, this compound is poised to play an increasingly significant role in addressing complex medical challenges through targeted molecular interventions.

• 915924-93-5(6-Oxo-1-propylpiperidine-3-carboxylic acid)
• 915924-95-7(1-Isobutyl-6-oxopiperidine-3-carboxylic acid)
• 926246-53-9(1-propanoylpiperidine-3-carboxylic acid)
• 183237-66-3(1-(2-propylpentanoyl)piperidine-3-carboxylic acid)
• 111333-82-5(3-Piperidinecarboxylic acid, 1-(1-oxohexyl)-)
• 926214-33-7(1-Isobutyryl-3-piperidinecarboxylic acid)
• 111333-85-8(3-Piperidinecarboxylic acid, 1-(1-oxododecyl)-)
• 22540-51-8(1-Methyl-6-oxopiperidine-3-carboxylic acid)
• 923177-08-6(1-(2,2-DIMETHYLPROPANOYL)PIPERIDINE-3-CARBOXYLIC ACID)
• 915919-82-3(1-Ethyl-6-oxopiperidine-3-carboxylic acid)